Walter M. Stadler to Sirolimus
This is a "connection" page, showing publications Walter M. Stadler has written about Sirolimus.
Connection Strength
1.350
-
Maturing of renal cancer therapeutics. J Clin Oncol. 2014 Mar 10; 32(8):722-4.
Score: 0.424
-
FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med. 2013 Aug; 2(4):545-52.
Score: 0.407
-
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer. 2020 07 15; 126(14):3237-3243.
Score: 0.163
-
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
Score: 0.087
-
Bevacizumab and everolimus in renal cancer: a rational way forward. J Clin Oncol. 2010 Nov 20; 28(33):e692-3; author reply e694.
Score: 0.084
-
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34.
Score: 0.075
-
Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res. 2005 Feb 01; 11(3):1181-9.
Score: 0.057
-
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004 Mar 01; 22(5):909-18.
Score: 0.053